CN102066372B - 含脲基的5，6元杂芳双环化合物作为激酶抑制剂 - Google Patents

含脲基的5，6元杂芳双环化合物作为激酶抑制剂 Download PDF

Info

Publication number
CN102066372B
CN102066372B CN201080001560.9A CN201080001560A CN102066372B CN 102066372 B CN102066372 B CN 102066372B CN 201080001560 A CN201080001560 A CN 201080001560A CN 102066372 B CN102066372 B CN 102066372B
Authority
CN
China
Prior art keywords
ylmethyl
pyridin
indol
pyrrole
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080001560.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102066372A (zh
Inventor
江山
邢兴龙
王其杉
孔韧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kong Jingxin
Original Assignee
ASCEPION PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ASCEPION PHARMACEUTICALS Inc filed Critical ASCEPION PHARMACEUTICALS Inc
Publication of CN102066372A publication Critical patent/CN102066372A/zh
Application granted granted Critical
Publication of CN102066372B publication Critical patent/CN102066372B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201080001560.9A 2009-08-24 2010-08-20 含脲基的5，6元杂芳双环化合物作为激酶抑制剂 Expired - Fee Related CN102066372B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23627409P 2009-08-24 2009-08-24
US61/236,274 2009-08-24
PCT/CN2010/076199 WO2011023081A1 (en) 2009-08-24 2010-08-20 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors

Publications (2)

Publication Number Publication Date
CN102066372A CN102066372A (zh) 2011-05-18
CN102066372B true CN102066372B (zh) 2014-09-17

Family

ID=43627250

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080001560.9A Expired - Fee Related CN102066372B (zh) 2009-08-24 2010-08-20 含脲基的5，6元杂芳双环化合物作为激酶抑制剂

Country Status (20)

Country Link
US (1) US8648086B2 (cg-RX-API-DMAC10.html)
EP (1) EP2470533A4 (cg-RX-API-DMAC10.html)
JP (1) JP2013502444A (cg-RX-API-DMAC10.html)
KR (1) KR20120089459A (cg-RX-API-DMAC10.html)
CN (1) CN102066372B (cg-RX-API-DMAC10.html)
AU (1) AU2010289143A1 (cg-RX-API-DMAC10.html)
BR (1) BR112012003462A2 (cg-RX-API-DMAC10.html)
CA (1) CA2769151A1 (cg-RX-API-DMAC10.html)
CO (1) CO6491087A2 (cg-RX-API-DMAC10.html)
EA (1) EA201290073A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP12011691A (cg-RX-API-DMAC10.html)
IL (1) IL218114A0 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN01983A (cg-RX-API-DMAC10.html)
MA (1) MA33559B1 (cg-RX-API-DMAC10.html)
MX (1) MX2012002317A (cg-RX-API-DMAC10.html)
PH (1) PH12012500366A1 (cg-RX-API-DMAC10.html)
SG (1) SG178092A1 (cg-RX-API-DMAC10.html)
TN (1) TN2012000042A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011023081A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201200890B (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
JP5583751B2 (ja) 2009-03-21 2014-09-03 クイ ニング アミノエステル誘導体、その塩、及び使用方法
CN103080109A (zh) * 2010-09-01 2013-05-01 苏州爱斯鹏药物研发有限责任公司 氘代杂环化合物激酶抑制剂
BR112013013659B8 (pt) 2010-12-03 2024-02-27 Epizyme Inc Compostos moduladores de enzimas epigenéticas, composição farmacêutica compreendendo ditos compostos e usos da dita composição farmacêutica para tratar câncer, câncer hematológico ou leucemia
CN102408426B (zh) * 2011-09-14 2013-07-10 湖南有色凯铂生物药业有限公司 取代的芳香脲类化合物及其作为抗癌药物的应用
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN103420895A (zh) * 2012-05-18 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种4-氨基吲哚的制备方法
US20150284422A1 (en) 2012-08-10 2015-10-08 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
WO2014039839A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
CA2903303A1 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
CN103613580B (zh) * 2013-09-03 2016-02-10 遵义医学院 用于抗肿瘤药物的3-羟基吲哚-2-酮类化合物或其药学上能够接受的盐
CN106279154A (zh) * 2016-08-02 2017-01-04 叶芳 一种7‑氮杂吲哚‑3‑甲醛的制备方法
CN108191874B (zh) * 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
EP3744718A4 (en) * 2018-06-01 2021-11-17 Adlai Nortye Biopharma Co., Ltd. HIGHLY ACTIVE CSF1R INHIBITOR CONNECTION
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
WO2022123319A1 (en) * 2020-12-11 2022-06-16 Ildong Pharmaceutical Co., Ltd. Biased agonists of opioid receptors
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500817B1 (en) * 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
CN1678573A (zh) * 2002-09-05 2005-10-05 神经研究公司 二芳基脲衍生物和它们作为氯通道阻滞剂的用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
HUP0001943A3 (en) 1997-01-23 2002-12-28 Smithkline Beecham Corp Benzimidazole and benzotriazole derivatives, their use, process for their preparation and pharmaceutical compositions containing them
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
WO2005047289A1 (en) * 2003-11-17 2005-05-26 Pfizer Products Inc. Pyrrolopyrimidine compounds useful in treatment of cancer
SI1696920T1 (sl) 2003-12-19 2015-02-27 Plexxikon Inc. Spojine in postopki za razvoj modulatorjev ret
WO2005073224A2 (en) * 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
RU2006138621A (ru) 2004-04-02 2008-05-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Азаиндолы, полезные в качестве ингибиторов rock и других протеинкиназ
AU2005265017A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CA2573573A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN102161653A (zh) 2004-11-24 2011-08-24 雅培制药有限公司 抑制香草素受体亚型1(vr1)受体的苯并二氢吡喃基脲化合物及其用途
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
CA2594449A1 (en) 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity
CA2598956A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
WO2007013896A2 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
MY153898A (en) 2005-06-22 2015-04-15 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JP5072595B2 (ja) * 2005-08-05 2012-11-14 中外製薬株式会社 マルチキナーゼ阻害剤
JP2007099642A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
KR20080075837A (ko) * 2005-10-28 2008-08-19 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
CN102516176A (zh) 2005-10-28 2012-06-27 雅培制药有限公司 抑制trpv1受体的吲唑衍生物
DK1962830T3 (da) 2005-12-23 2013-06-24 Glaxosmithkline Llc Azaindolhæmmere af aurorakinaser.
US20090018156A1 (en) 2006-02-01 2009-01-15 Jun Tang Pyrrolo [2,3,B] Pyridine Derivatives Useful As RAF Kinase Inhibitors
CN101058561B (zh) * 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
CN101636397B (zh) * 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 脲类化合物、其制备方法及其医药用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500817B1 (en) * 1999-03-08 2002-12-31 Bayer Aktiengesellschaft Thiazolyl urea derivatives and their utilization as antiviral agents
CN1678573A (zh) * 2002-09-05 2005-10-05 神经研究公司 二芳基脲衍生物和它们作为氯通道阻滞剂的用途

Also Published As

Publication number Publication date
US20120122895A1 (en) 2012-05-17
CN102066372A (zh) 2011-05-18
PH12012500366A1 (en) 2012-10-22
AU2010289143A1 (en) 2012-02-16
EP2470533A4 (en) 2013-01-23
WO2011023081A1 (en) 2011-03-03
MX2012002317A (es) 2012-06-25
JP2013502444A (ja) 2013-01-24
IN2012DN01983A (cg-RX-API-DMAC10.html) 2015-07-24
KR20120089459A (ko) 2012-08-10
EP2470533A1 (en) 2012-07-04
SG178092A1 (en) 2012-03-29
US8648086B2 (en) 2014-02-11
TN2012000042A1 (en) 2013-09-19
MA33559B1 (fr) 2012-09-01
ZA201200890B (en) 2012-10-31
ECSP12011691A (es) 2012-04-30
BR112012003462A2 (pt) 2016-02-23
EA201290073A1 (ru) 2013-01-30
IL218114A0 (en) 2012-04-30
CA2769151A1 (en) 2011-03-03
CO6491087A2 (es) 2012-07-31

Similar Documents

Publication Publication Date Title
CN102066372B (zh) 含脲基的5，6元杂芳双环化合物作为激酶抑制剂
CN115677702B (zh) 三并环化合物及其药物组合物和应用
CN105814050B (zh) 用作tnf活性调节剂的吡唑并吡啶衍生物
WO2021218755A1 (zh) Shp2抑制剂及其组合物和应用
US8436011B2 (en) Pyridinopyridinone derivatives, preparation thereof and therapeutic use thereof
JP7337395B2 (ja) Ｃｄｋ４およびｃｄｋ６阻害剤としての２ｈ－インダゾール誘導体およびその治療上の使用
CN113454081B (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
CA2568608C (en) Six membered amino-amide derivatives as angiogenesis inhibitors
CN102372717B (zh) 吡咯并嘧啶类化合物及其用途
JP6969800B2 (ja) 増殖性疾患の治療に使用される置換２，４−ジアミノ−キノリン誘導体
CN107383014A (zh) 一种1H‑吡唑并[3,4‑d]嘧啶类化合物及其制备方法和应用
WO2022242697A1 (zh) Tyk2选择性抑制剂及其用途
CN110156802A (zh) 脲取代的芳环连二噁烷并喹啉类化合物及其制备方法与应用
CN107879975A (zh) 组蛋白去乙酰化酶抑制剂及其应用
WO2012028106A1 (en) Deuterium-enriched heterocyclic compounds as kinase inhibitors
WO2008098096A1 (en) Anti-cytokine heterocyclic compounds
TW202321232A (zh) 小分子sting拮抗劑
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
WO2022002100A1 (zh) 新型苯并咪唑化合物
CN110467616B (zh) 含杂芳基取代哒嗪酮结构的三唑并吡嗪类化合物的制备及应用
TW202035406A (zh) 作為cdk-hdac雙通路抑制劑的雜環化合物
WO2019154133A1 (zh) 二噁烷并喹啉类化合物及其制备方法与应用
CN117396463A (zh) 用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法和含有其作为活性成分的药物组合物
WO2022098970A9 (en) Pyrazole derivatives as ret kinase inhibitors
WO2022017524A1 (zh) 吡啶酮类化合物及其制备方法和应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1157779

Country of ref document: HK

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20110518

Assignee: Swiss pharmaceutical group

Assignor: Ascepion Pharmaceuticals, Inc.

Contract record no.: 2012990000587

Denomination of invention: 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors

License type: Exclusive License

Record date: 20120810

EC01 Cancellation of recordation of patent licensing contract

Assignee: Swiss pharmaceutical group

Assignor: Ascepion Pharmaceuticals, Inc.

Contract record no.: 2012990000587

Date of cancellation: 20130605

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160913

Address after: 530000, No. 89 East University Road, West Tong District, the Guangxi Zhuang Autonomous Region, Nanning

Patentee after: Kong Jingxin

Address before: Chinese Park in Suzhou city of Jiangsu province Xinghu Street No. 218 biological nano science and Technology Park building A3 Room 102

Patentee before: Ascepion Pharmaceuticals, Inc.

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1157779

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140917

Termination date: 20170820